Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534268 | 1.00 | KMT2A (0.68) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL10414069 | 0.94 | KMT2A (0.76) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL10414068 | 0.94 | KMT2A (0.76) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL11688124 | 0.91 | KMT2A (0.81) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL4778536 | 0.91 | KMT2A (0.81) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL4778528 | 0.91 | KMT2A (0.81) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL14047083 | 0.90 | KMT2A (0.69) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL14271668 | 0.86 | KMT2A (0.64) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL435677 | 0.85 | KMT2A (0.74) | KMT2AMEN1NR1H4MAPTALDH1A1 | |
| SCHEMBL10505912 | 0.84 | MEN1 (0.74) | KMT2AMEN1NR1H4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| EP-0612244-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6274737-B1 | CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-08-14 | — | — | US | disclosed |
| US-6271399-B1 | METHYL 3-(3,4-METHYLENEDIOXYPHENYL)-6-(PROP-1-YLOXY)-INDANE-2-CARBOXYLATE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5716984-A | INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0612244-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-17 | — | — | EP | disclosed |
| EP-0612244-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993008799-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | KMT2A 3924/4885MEN1 2858/4885NR1H4 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.